In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Checkpoint Therapeutics Inc (CKPT – Research Report), with a price target of $11. The company’s shares closed on Friday at $3.15.
“Valuation and risks to price target achievement. We reiterate our Buy rating and $11 price target. Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s two lead assets, CK-301 and CK-101. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway.”
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -20.5% and a 23.2% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Strata Skin Sciences Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Checkpoint Therapeutics Inc with a $11 average price target.
The company has a one-year high of $6.29 and a one-year low of $1.50. Currently, Checkpoint Therapeutics Inc has an average volume of 67.87K.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CKPT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializes in the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers.